mature T cell proliferation 1Genealiases: P13MTCP1 · TCL1C · p8MTCP1
Q-omics provides the consensus-scored MTCP1 profile across patient tissues and cancer cell-line models. MTCP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MTCP1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MTCP1 RNA expression shows 19,839 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where MTCP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCP1 survival associations across molecular data types. MTCP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCP1 RNA expression–survival associations across cancer types. High MTCP1 expression shows unfavorable associations in KICH, LIHC, LGG, ACC and UCEC, but favorable associations in SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for MTCP1 RNA expression.
This table summarizes MTCP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MTCP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCP1 shows lower tumor expression in THCA and higher tumor expression in KIRC, BLCA, HNSC, KIRP and STAD. The KIRC box plot shows higher MTCP1 RNA expression in tumor versus normal tissue (log2 FC = +2.280, t-test p < 0.001).
This table shows molecular features associated with MTCP1 in patient tissues and cancer cell lines. In patient samples, MTCP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTCP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and CNS.
